Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBITDA MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginReturn on AssetsReturn on EquityReturn on Sales

Summit Therapeutics (SMMT) FCF Margin (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed FCF Margin for 1 consecutive years, with 540966.67% as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, FCF Margin changed N/A year-over-year to 540966.67%, compared with a TTM value of 2998255.56% through Sep 2025, up 299643941.0%, and an annual FY2022 reading of 5986.67%, down 195720.0% over the prior year.
  • FCF Margin was 540966.67% for Q4 2024 at Summit Therapeutics, up from 1063.77% in the prior quarter.
  • Across five years, FCF Margin topped out at 540966.67% in Q4 2024 and bottomed at 965.65% in Q1 2024.